In the BioHarmony Drug Report Database

"Preview" Icon

Elvitegravir

Vitekta, Genvoya (elvitegravir) is a small molecule pharmaceutical. Elvitegravir was first approved as Vitekta on 2014-09-24. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. Stribild’s patents are valid until 2026-10-26 (FDA).

 

Trade Name

 

Genvoya
 

Common Name

 

elvitegravir
 

ChEMBL ID

 

CHEMBL204656
 

Indication

 

hiv infections
 

Drug Class

 

Antivirals: integrase inhibitors

Image (chem structure or protein)

Elvitegravir structure rendering